Valuation: Indivior Pharmaceuticals, Inc.

Market Cap 4.35B 3.73B 3.49B 3.19B 5.99B 416B 6.07B 41.2B 16.07B 209B 16.34B 15.98B 692B P/E 2026 *
9.91x
P/E 2027 * 8.98x
Enterprise Value 4.34B 3.72B 3.48B 3.18B 5.97B 415B 6.05B 41.08B 16.02B 209B 16.29B 15.94B 690B EV / Sales 2026 *
3.26x
EV / Sales 2027 * 2.7x
Free-Float
97.98%
Yield 2026 *
-
Yield 2027 * -
1 day-2.41%
1 week-5.49%
Current month-7.85%
1 month-8.85%
3 months-1.76%
6 months+8.79%
Current year+2.76%
1 week 36.7
Extreme 36.7
40
1 month 35.76
Extreme 35.76
41.65
Current year 27.68
Extreme 27.68
42.81
1 year 22.22
Extreme 22.22
42.81
3 years 7.33
Extreme 7.33
42.81
5 years 7.33
Extreme 7.33
42.81
10 years 1.75
Extreme 1.75
42.81
Date Insider Type Main position Quantity % Market Cap.
5/8/26 Buy

Controller/Auditor

1,500 0.0012%
10/7/26 Sell

Chief Scientific Officer

-18,586 0.0152%
13/5/26 Free

Director

6,518 0.0053%
Change 5-day change 1-year change 3-year change Capi.($)
-2.41%-5.49%+51.60%+59.89% 4.35B
+0.88%+6.38%+76.40%+126.75% 1,119B
+1.07%+3.80%+50.73%+62.78% 651B
+1.20%+6.21%+25.81%+78.74% 468B
+1.02%+5.77%+43.63%+48.43% 374B
+0.85%+4.07%+24.97%+40.58% 302B
+1.26%+6.81%+2.27%+14.41% 259B
+1.88%+5.81%+49.57%+70.53% 238B
+1.59%+2.09%-17.33%-52.62% 208B
+1.87%+5.61%+27.32%+91.38% 181B
Average +0.92%+3.93%+33.50%+54.09% 380.42B
Weighted average by Cap. +1.13%+5.08%+44.27%+72.63%

Financials

2026 *2027 *
Net sales 1.33B 1.14B 1.07B 977M 1.83B 127B 1.86B 12.61B 4.92B 64.02B 5B 4.89B 212B 1.4B 1.2B 1.12B 1.03B 1.93B 134B 1.95B 13.25B 5.17B 67.27B 5.26B 5.14B 222B
Net income 474M 406M 380M 348M 653M 45.38B 662M 4.49B 1.75B 22.8B 1.78B 1.74B 75.4B 530M 454M 425M 389M 730M 50.71B 739M 5.02B 1.96B 25.47B 1.99B 1.95B 84.25B
Net Debt -12.5M -10.71M -10.02M -9.17M -17.21M -1.2B -17.44M -118M -46.16M -601M -46.94M -45.92M -1.99B -570M -488M -457M -418M -785M -54.54B -795M -5.4B -2.1B -27.4B -2.14B -2.09B -90.62B
Logo Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
833
Date Price Change Volume
21/08/26 USD 36.87 -2.41% 2,496,842
20/08/26 USD 37.78 -3.23% 1,442,328
19/08/26 USD 39.04 -0.99% 2,476,877
18/08/26 USD 39.43 +0.90% 2,338,564
17/08/26 USD 39.08 +0.18% 2,018,200
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
36.87USD
Average target price
49.00USD
Spread / Average Target
+32.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INDV Stock